Apollo Hospitals gets NCLT nod for restructuring of digital and pharmacy businesses
April 03, 2026
Apollo Hospitals gets NCLT nod for restructuring plan, including spin-off of digital and pharmacy business, pending stakeholder and regulatory approvals.
Apollo Hospitals Enterprise has received a key regulatory nod required for its proposed corporate restructuring.
The healthcare major informed exchanges on Friday that the National Company Law Tribunal (NCLT), Chennai bench, has approved its application for its proposed composite scheme of arrangement involving the restructuring of Apollo’s healthcare and allied businesses across four entities- Apollo Hospitals Enterprise Ltd, Apollo Healthco Ltd, Keimed Pvt Ltd, and Apollo Healthtech Ltd. It is essentially a restructuring of its digital and pharmacy businesses, as well as its listing.
Next step: stakeholder approvals
In an order dated March 26, 2026, the NCLT allowed the application and directed the company to convene meetings of equity shareholders, secured creditors, and unsecured creditors to consider and approve the scheme.
It remains subject to stakeholder approvals, regulatory clearances, and the tribunal’s final sanction.
Earlier regulatory clearances
The company, earlier in December, received a ‘no-objection’ from the exchanges (NSE and BSE) for its scheme to restructure its businesses.
Earlier in September, the healthcare major had also received approval from the Competition Commission of India (CCI) for the transactions contemplated under the scheme.
Details of restructuring plan
Under the scheme, which was first approved in July by Apollo’s Board, the omnichannel pharma and digital health business will be spun off into a new, unnamed entity. Subsequently, Apollo’s omnichannel healthcare arm, Apollo HealthCo (AHL) and wholesale pharma distributor Keimed Private Ltd will be merged with the new entity.
Published on April 3, 2026
The healthcare major informed exchanges on Friday that the National Company Law Tribunal (NCLT), Chennai bench, has approved its application for its proposed composite scheme of arrangement involving the restructuring of Apollo’s healthcare and allied businesses across four entities- Apollo Hospitals Enterprise Ltd, Apollo Healthco Ltd, Keimed Pvt Ltd, and Apollo Healthtech Ltd. It is essentially a restructuring of its digital and pharmacy businesses, as well as its listing.
Next step: stakeholder approvals
In an order dated March 26, 2026, the NCLT allowed the application and directed the company to convene meetings of equity shareholders, secured creditors, and unsecured creditors to consider and approve the scheme.
It remains subject to stakeholder approvals, regulatory clearances, and the tribunal’s final sanction.
Earlier regulatory clearances
The company, earlier in December, received a ‘no-objection’ from the exchanges (NSE and BSE) for its scheme to restructure its businesses.
Earlier in September, the healthcare major had also received approval from the Competition Commission of India (CCI) for the transactions contemplated under the scheme.
Details of restructuring plan
Under the scheme, which was first approved in July by Apollo’s Board, the omnichannel pharma and digital health business will be spun off into a new, unnamed entity. Subsequently, Apollo’s omnichannel healthcare arm, Apollo HealthCo (AHL) and wholesale pharma distributor Keimed Private Ltd will be merged with the new entity.
Published on April 3, 2026